<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116661</url>
  </required_header>
  <id_info>
    <org_study_id>10101</org_study_id>
    <nct_id>NCT01116661</nct_id>
  </id_info>
  <brief_title>Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain</brief_title>
  <acronym>ALA</acronym>
  <official_title>A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prodrug, 5-Aminolevulinic acid (ALA), has been shown to lead to intracellular
      accumulation of fluorescent porphyrins in high grade malignant gliomas in the brain. On
      imaging, this accumulation of fluorescent porphyrins helps delineate tumor borders, resulting
      in the surgeon being better able to visualize and thus able to make a complete, or
      near-complete resection of the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug, 5-aminolevulinic acid (ALA), which leads to intracellular accumulation of
      fluorescent porphyrins in gliomas will be used under investigation for identification and
      resection of high and low grade gliomas. Surgery will be done using a modified neurosurgical
      microscope, with a fluorescent kit that enables switching from the conventional white light
      to a violet-blue excitation light for visualization during tumor resection. If deemed safe by
      the neurosurgeon, any area of the resection bed determined to be fluorescence-positive for
      tumor will be removed with appropriate designation of tissue for histopathological
      evaluation. After this resection, additional fluorescence images will be obtained and the
      process repeated until the image is negative for tumor. At all times, the decision to resect
      will be limited by clinical judgment of safety.

      The desire is that a more complete resection will occur due to the surgeon's ability to
      better visualize and distinguish between tumor and normal tissue, and thus be able to remove
      as much, or most of, the tumorous tissue, resulting in a better outcome for the patient, or
      for future patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The primary objective for high grade gliomas has been met and the FDA has now approved the drug
    (Gleolan) for use in the United States.
  </why_stopped>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">December 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Biopsies Taken From the Most Fluorescent Tissues That Have Tumorous Content.</measure>
    <time_frame>1 day</time_frame>
    <description>Biopsies were examined by a pathologist to determine the amount of tumor content from the most fluorescent tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>14 days</time_frame>
    <description>Number of Participants with Adverse Events, as defined by grade 3 to 5 AEs and SAEs related to study drug. .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>ALA for glioma (WHO G1-IV) subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 300 patients with diagnosed glioma (WHO G1-IV) eligible for surgery will be entered into the trial and will be given 5-Aminolevulinic Acid (ALA) orally at a dose of 20mg/kg body weight preoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Aminolevuline Acid (ALA)</intervention_name>
    <description>Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery</description>
    <arm_group_label>ALA for glioma (WHO G1-IV) subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Presumptive diagnosis of high grade or low grade glioma based on imaging studies, or
             will have recurrent high-grade or low grade gliomas that have previously undergone
             diagnosis (astrocytoma, oligodendroglioma, mixed oligo-astrocytoma, anaplastic
             astrocytoma, and glioblastoma multiforme). Both of these groups will be undergoing
             craniotomy for tumor resection.

          2. Patient age 18 to 72 years.

          3. Karnofsky performance of 60% or greater

          4. Patients must have normal organ and marrow function as defined below:

             Leukocytes &gt;3,000/μL Absolute neutrophil count &gt;1,500/μL Platelets &gt;100,000/μL Total
             bilirubin within normal institutional limits AST (SGOT)/ALT (SGPT) &lt;2.5 X
             institutional upper limit of normal Creatinine within normal institutional limits or
             Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above
             institutional normal.

          5. The effects of Aminolevulinic Acid (ALA) on the developing human fetus are unknown.
             Therefore, women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation.

          6. Patient must have the ability to understand and the willingness to sign a written
             informed consent document or have a parent or guardian with the ability to understand
             and the willingness to sign the written informed consent.

        Exclusion Criteria:

          1. Subjects with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to aminolevulinic acid (ALA).

          2. Subjects with a history or family history of Porphyrias

          3. Subjects with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements.

          4. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel S Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Department of Neurosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Department of Neurosurgery</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <results_first_submitted>December 27, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Mitchel Berger</investigator_full_name>
    <investigator_title>MD, Chairman</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>high grade glioma, low grade glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT01116661/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Dose ALA for Newly Diagnosed and Recurrent HGG</title>
          <description>5-Aminolevuline Acid: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery for both newly diagnosed and recurrent High grade gliomas</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population is the same as the assignment in Participant flow</population>
      <group_list>
        <group group_id="B1">
          <title>5 - Aminolevuline Acid in Patients With HGG</title>
          <description>5-Aminolevuline Acid: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Study did not allow for participates under 18 years of age</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Biopsies Taken From the Most Fluorescent Tissues That Have Tumorous Content.</title>
        <description>Biopsies were examined by a pathologist to determine the amount of tumor content from the most fluorescent tissues</description>
        <time_frame>1 day</time_frame>
        <population>All patient who received 5-Aminolevuline Acid prior to surgical resection</population>
        <group_list>
          <group group_id="O1">
            <title>5- Aminolevuline Acid Given to HGG Participants</title>
            <description>5-Aminolevuline Acid: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Biopsies Taken From the Most Fluorescent Tissues That Have Tumorous Content.</title>
          <description>Biopsies were examined by a pathologist to determine the amount of tumor content from the most fluorescent tissues</description>
          <population>All patient who received 5-Aminolevuline Acid prior to surgical resection</population>
          <units>percentage of biopsies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="9.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of Participants with Adverse Events, as defined by grade 3 to 5 AEs and SAEs related to study drug. .</description>
        <time_frame>14 days</time_frame>
        <population>Patients who received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>5- Aminolevuline Acid Given to HGG Participants</title>
            <description>5-Aminolevuline Acid: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of Participants with Adverse Events, as defined by grade 3 to 5 AEs and SAEs related to study drug. .</description>
          <population>Patients who received study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of ALA dosing up to 14 days post- operative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5- Aminolevuline Acid Given to HGG Participants</title>
          <description>5-Aminolevuline Acid: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - with Grade 3 or 4 nuetrophils</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Infection - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Vascular - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hemoglobin decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT,SGPT increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>AST,SGOT increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>metabolic/Laboratory - other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dermatology/skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pain - skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitch Berger, MD; Director of Neurosurgery</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-353-7500</phone>
      <email>Mtich.Berger@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

